Abstract
Psoriasis is a chronic skin disease and the TNF‐α is the therapeutic target of this disease. The experiments including SPR and in vivo tests discovered the ergosterols from the fungus Aspergillus sp. TJ507 serve as lead structures for the development of novel TNF‐α inhibitory agents in the clinical treatment of psoriasis. More details are discussed in the article by Zhang et al. on page 743—751.image
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
